Nasus Pharma Ltd Archives - CatalystPICR

Nasus Pharma Ltd. ($NSRX) shares falling 9% in pre-market on Reporting...

NewsDesk - March 17, 2026 8:43 am

Nasus Pharma ($NSRX) Reports Positive Phase 2 Results for NS002 Intranasal...

Staff Writer - March 16, 2026 8:04 am

CATALYST News

Outlook Therapeutics ($OTLK) Secures FDA Approval for LYTENAVA™

NewsDesk - July 24, 2026 3:10 pm

Charter Communications ($CHTR) Beats Q2 EPS Estimates; Revenue Decline Driven by Lower Video Revenue

NewsDesk - July 24, 2026 8:21 am

SLB ($SLB) Q2 performance beats expectations; EBITDA and cash flow robust

Staff Writer - July 24, 2026 8:13 am

Sensient Technologies ($SXT) Beats Q2 EPS and Revenue Estimates; Projects Strong FY26 EPS

NewsDesk - July 24, 2026 8:02 am

American Express ($AXP) Beats EPS Estimates; Revenue Misses Amid Strong YoY Growth

Catalyst Desk - July 24, 2026 8:00 am

American Express ($AXP) Beats EPS Estimates; Revenue Misses Amid Strong YoY Growth

Catalyst Desk - July 24, 2026 8:00 am

FDA Approves MannKind’s ($MNKD) Furoscix ReadyFlow for Heart Failure and CKD

NewsDesk - July 24, 2026 7:25 am

Inhibikase ($IKT) Receives FDA Orphan Drug Designation for IKT-001

Catalyst Desk - July 23, 2026 8:23 am

Tesla ($TSLA) Q2 Earnings Miss Expectations; Revenue Surges YoY

Staff Writer - July 22, 2026 5:36 pm

IBM ($IBM) Exceeds Q2 EPS and Revenue Estimates; Software Revenue Up

NewsDesk - July 22, 2026 5:13 pm